Ensign Peak Advisors
TMO icon

Ensign Peak Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Ensign Peak Advisors’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$254M Sell
516,570
-232,605
-31% -$126M 0.47% 38
2025
Q4 		$434M Sell
749,175
-48,419
-6% -$27.4M 0.77% 20
2025
Q3 		$387M Buy
797,594
+271,007
+51% +$126M 0.63% 28
2025
Q2 		$214M Sell
526,587
-246,822
-32% -$103M 0.37% 56
2025
Q1 		$385M Sell
773,409
-287,534
-27% -$156M 0.74% 22
2024
Q4 		$552M Sell
1,060,943
-22,086
-2% -$12.1M 0.98% 14
2024
Q3 		$670M Sell
1,083,029
-90,466
-8% -$53.6M 1.18% 12
2024
Q2 		$649M Sell
1,173,495
-46,164
-4% -$26.4M 1.19% 13
2024
Q1 		$709M Buy
1,219,659
+132,781
+12% +$74.5M 1.29% 11
2023
Q4 		$577M Buy
1,086,878
+233,126
+27% +$113M 1.14% 11
2023
Q3 		$432M Buy
853,752
+62,973
+8% +$33.6M 0.92% 17
2023
Q2 		$413M Buy
790,779
+23,195
+3% +$12.5M 0.84% 18
2023
Q1 		$442M Buy
767,584
+2,863
+0.4% +$1.61M 0.96% 17
2022
Q4 		$421M Sell
764,721
-14,563
-2% -$7.72M 0.95% 19
2022
Q3 		$395M Buy
779,284
+19,273
+3% +$10.8M 0.98% 15
2022
Q2 		$413M Buy
760,011
+6,694
+0.9% +$3.68M 0.98% 15
2022
Q1 		$445M Sell
753,317
-51,943
-6% -$29.8M 0.9% 21
2021
Q4 		$537M Sell
805,260
-16,682
-2% -$10.4M 1.03% 12
2021
Q3 		$470M Sell
821,942
-34,857
-4% -$19.1M 0.98% 12
2021
Q2 		$432M Sell
856,799
-19,822
-2% -$9.35M 0.87% 17
2021
Q1 		$400M Sell
876,621
-61,007
-7% -$29.1M 0.86% 17
2020
Q4 		$437M Sell
937,628
-46,102
-5% -$21.6M 0.99% 13
2020
Q3 		$434M Sell
983,730
-39,505
-4% -$16.3M 1.1% 12
2020
Q2 		$371M Sell
1,023,235
-34,022
-3% -$11.4M 1.01% 12
2020
Q1 		$300M Sell
1,057,257
-886
-0.1% -$279K 1% 15
2019
Q4 		$344M Buy
+1,058,143
New +$321M 0.91% 17

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ensign Peak Advisors's TMO Position: Q1 2026 in Review

Ensign Peak Advisors reduced its Thermo Fisher Scientific (TMO) stake by 31% in Q1 2026, selling an estimated $126M and leaving 516,570 shares worth $254M. The position accounts for 0.47% of the portfolio, ranked #38.

Ensign Peak Advisors first reported a position in TMO in Q4 2019 and has held it in 26 quarters since. The position peaked at $709M in Q1 2024. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Ensign Peak Advisors held 516,570 shares of Thermo Fisher Scientific worth $254M as of Q1 2026.
  • Ensign Peak Advisors sold 232,605 Thermo Fisher Scientific shares in Q1 2026, an estimated $126M.
  • Thermo Fisher Scientific made up 0.47% of Ensign Peak Advisors's portfolio in Q1 2026, its #38 holding.
  • Ensign Peak Advisors first reported a position in Thermo Fisher Scientific in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Thermo Fisher Scientific position peaked at $709M in Q1 2024.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.